|
Focus: Automated Cell-Based AssaysAutomating Cell-Based Assays in Multiwell Format
By Tracy Worzella, B.S. and Brad Larson, B.A., Promega CorporationIntroduction Cell-based assays have become a quick, lower-cost means to test hit or lead
compounds for toxic effects before proceeding with drug development. The term
“cell-based assay” describes any procedure that uses The process of performing a cell-based assay generally includes plating
cells, equilibrating to culture conditions, adding a test compound, and
measuring output from treatment. These assays can be made easier by automating
the process. Depending on the needs and financial resources of the user, a
single step or multiple steps of the assay process can be adapted to an
automated workstation. These workstations, whether they are liquid handlers or
fully-integrated systems with incubators, shakers and plate readers, allow
increased throughput for sample processing. Automation also removes the
requirement for hands-on assay performance, resulting in less error and higher
reproducibility.
Automated Method Development Automated, single-plate methods were developed for five Promega cell-based assays in 96- and 384-well format on the Biomek® 2000 and FX workstations. Each method is a computer program that the robot will follow in order to perform the assay. These instructions encompass all the liquid handling steps, physical manipulations of each assay plate across the deck and operation of any devices on the deck. To perform a cell-based assay on an automated workstation, the deck of the
workstation is manually The automated cell-based assay methods we developed perform three steps on the robotic platform (Table 2). Additional steps, including assay plate incubations and recording data from fluorescent or luminescent assays, are performed offline (separate from the robotic platform). These steps can be automated, depending on the level of automation required on the robotic platform being used. This fact, along with the methods’ simplicity, and minimal deck requirements, allows these assays to meet the needs of low-, medium-, or high-throughput research laboratories. Validated methods to run these assays and other chemistries are available for
download at www.promega.com/automethods/. In
addition, the hardware, labware requirements and instructions are available as
automated protocols and are available at www.promega.com/tbs/.
Validation and Results The criteria that we use for validation include the sensitivity of each assay, as well as linearity across a set range of cell or purified enzyme concentrations. Assay robustness and reproducibility are tested as well using Z´-factor determination (1). The Z´-factor is a statistical value used to determine an assay’s robustness and reproducibility by comparing its dynamic range to the data variation. A Z´-factor value of 1.0 indicates a perfect assay. A Z´-factor value greater than 0.5 indicates excellent assay quality. The Z´-factor was determined for each automated assay. Analyses were completed in 96- and 384-well formats using the Biomek® 2000 and Biomek® FX platforms. The results from each analysis are shown in Table 3. All assays and formats had a Z´-factor greater than 0.5.
Summary We have demonstrated the ability to automate Promega’s cell-based assays in
both 96- and 384-well formats. Z´-factors for each assay format were above 0.5,
indicating that they were all excellent assays. Reference
Products may be covered by pending or issued patents or may have certain limitations on use. Please visit our patent and trademark web page for more information.Apo-ONE and CellTiter-Glo are trademarks of Promega Corporation and are registered with the U.S. Patent and Trademark Office. Caspase-Glo, CellTiter-Blue and CytoTox-ONE are trademarks of Promega Corporation.Biomek is a registered trademark of Beckman Coulter, Inc. |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||